TiGenix – American Depositary Shares (NASDAQ:TIG) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “TiGenix NV is a biopharmaceutical company. It focused on developing and commercializing novel therapeutics for allogeneic or donor-derived, expanded stem cells. The company’s product platform consists of Cx601 and Cx611 which are in clinical trial stage. It operates primarily in Madrid, Spain. TiGenix NV is based in Leuven, Belgium. “

Several other equities analysts have also recently weighed in on the company. Canaccord Genuity set a $30.00 price objective on TiGenix – American Depositary Shares and gave the company a “buy” rating in a report on Tuesday, December 12th. BidaskClub cut TiGenix – American Depositary Shares from a “sell” rating to a “strong sell” rating in a report on Saturday, December 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. TiGenix – American Depositary Shares presently has an average rating of “Hold” and an average target price of $29.27.

Shares of TiGenix – American Depositary Shares (TIG) traded up $0.01 on Friday, reaching $40.74. The company’s stock had a trading volume of 40,800 shares, compared to its average volume of 16,227. TiGenix – American Depositary Shares has a 12-month low of $14.30 and a 12-month high of $41.00. The company has a current ratio of 1.37, a quick ratio of 1.36 and a debt-to-equity ratio of 0.10.

A hedge fund recently bought a new stake in TiGenix – American Depositary Shares stock. EAM Investors LLC purchased a new position in shares of TiGenix – American Depositary Shares (NASDAQ:TIG) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned about 1.20% of TiGenix – American Depositary Shares as of its most recent SEC filing. 5.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/tigenix-american-depositary-shares-tig-lowered-to-hold-at-zacks-investment-research/1799028.html.

About TiGenix – American Depositary Shares

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Get a free copy of the Zacks research report on TiGenix – American Depositary Shares (TIG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with Analyst Ratings Network's FREE daily email newsletter.